NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Screener

MGX

Metagenomi Inc

Jul 01 • 10:50AM ET

1.50

Dollar change +0.02
Percentage change 1.69	%

Healthcare • Biotechnology • USA • NASD

Peers: NTLA CRSP EDIT BEAM VERV PRME DNLI VRTX SGMO ARCT

| Held by: VTI VXF VTWO IWM IWC VTWG IWO VTWV IWN VTHR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.10	Insider Own	41.67%	Shs Outstand	37.38M	Perf Week	-2.27%
Market Cap	56.25M	Forward P/E	-	EPS next Y	-2.08	Insider Trans	-0.17%	Shs Float	21.80M	Perf Month	-11.47%
Enterprise Value	-125.28M	PEG	-	EPS next Q	-0.62	Inst Own	24.90%	Short Float	9.61%	Perf Quarter	10.66%
Income	-77.95M	P/S	1.24	EPS this Y	-3.60%	Inst Trans	5.18%	Short Ratio	4.65	Perf Half Y	-62.66%
Sales	45.26M	P/B	0.26	EPS next Y	14.95%	ROA	-21.86%	Short Interest	2.10M	Perf YTD	-58.31%
Book/sh	5.69	P/C	0.25	EPS next 5Y	-14.66%	ROE	-31.93%	52W High	5.50 -72.64%	Perf Year	-60.08%
Cash/sh	6.05	P/FCF	-	EPS past 3/5Y	-53.91% -	ROIC	-30.99%	52W Low	1.23 22.36%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	499.26% -	Gross Margin	87.87%	Volatility	9.34% 8.36%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-2.77	EPS Y/Y TTM	18.67%	Oper. Margin	-193.73%	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.85	Sales Y/Y TTM	-4.22%	Profit Margin	-172.21%	RSI (14)	46.70	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	5.85	EPS Q/Q	43.15%	SMA20	-2.45%	Beta	-0.38	Target Price	10.75
Payout	-	Debt/Eq	0.21	Sales Q/Q	-63.02%	SMA50	-5.93%	Rel Volume	0.87	Prev Close	1.48
Employees	202	LT Debt/Eq	0.18	Earnings	May 13 AMC	SMA200	-29.59%	Avg Volume	451.04K	Price	1.50
IPO	Feb 09, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-11.75% -50.28%	Trades		Volume	96,229	Change	1.69%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Initiated	H.C. Wainwright	Buy	$10
May-02-24	Downgrade	JP Morgan	Overweight → Neutral	$16 → $6
Mar-05-24	Initiated	Wells Fargo	Overweight	$25
Mar-05-24	Initiated	TD Cowen	Outperform
Mar-05-24	Initiated	JP Morgan	Overweight	$16
Mar-05-24	Initiated	Jefferies	Buy	$23
Mar-05-24	Initiated	Chardan Capital Markets	Buy	$21
Mar-05-24	Initiated	BMO Capital Markets	Outperform	$22

May-14-25 06:00AM	Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025 (GlobeNewswire) -6.25%
May-13-25 05:40PM	Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:42PM	Metagenomi: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	Metagenomi Reports Business Updates and First Quarter 2025 Financial Results (GlobeNewswire)
May-08-25 09:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +9.66%
07:15AM	Loading…
May-06-25 07:15AM	Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.96%
May-02-25 07:00AM	Metagenomi to Present at Upcoming Scientific Meetings (GlobeNewswire) +8.05%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-17-25 04:05PM	Metagenomi Reports Business Updates and Full Year 2024 Financial Results (GlobeNewswire) -7.98%
Mar-13-25 06:19AM	Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems (GlobeNewswire) -6.83%
Feb-11-25 08:55AM	Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference (GlobeNewswire) -6.17%
Jan-28-25 08:00AM	Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer (GlobeNewswire)
Jan-22-25 11:54AM	People are buying the wrong stock thinking it's part of OpenAI's Stargate Project (Quartz) +11.40%
Jan-16-25 08:55AM	Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones (GlobeNewswire)
Jan-15-25 08:55AM	Metagenomi Announces New Appointment to its Board of Directors (GlobeNewswire)
04:05PM	Loading…
Jan-08-25 04:05PM	Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.36%
Dec-11-24 06:30PM	Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference RNA at the Bench and Bedside IV (GlobeNewswire) -5.73%
Dec-09-24 09:16PM	Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting (GlobeNewswire) +125.41%
Dec-08-24 06:05AM	Jefferies Predicts Up to ~1000% Surge for These 2 Strong Buy Stocks (TipRanks)
Nov-18-24 12:00PM	What Makes Metagenomi (MGX) a New Buy Stock (Zacks)
Nov-13-24 04:37PM	Metagenomi: Q3 Earnings Snapshot (Associated Press Finance) -10.90%
04:05PM	Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 04:05PM	Metagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual Meeting (GlobeNewswire)
Oct-29-24 05:45AM	Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
Oct-24-24 08:04AM	Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT (GlobeNewswire)
Oct-23-24 05:45AM	Investors in Metagenomi, Inc. Should Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
Oct-14-24 08:58PM	Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies (GlobeNewswire)
Oct-01-24 03:14PM	Metagenomi, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
Sep-19-24 07:15PM	Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -6.84%
Sep-03-24 04:05PM	Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months (GlobeNewswire)
07:32PM	Loading…
Aug-29-24 07:32PM	Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference (GlobeNewswire)
Aug-28-24 06:10PM	Metagenomi to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
Aug-26-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Metagenomi, Target Hospitality, Helios, and LegalZoom and Encourages Investors to Contact the Firm (GlobeNewswire)
Aug-14-24 08:11AM	Metagenomi: Q2 Earnings Snapshot (Associated Press Finance)
08:05AM	Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 06:29PM	Metagenomi, Inc. (MGX): This New Penny Stock Received a Positive Rating From Street Analysts (Insider Monkey) +10.54%
Aug-05-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Dril-Quip, LPL Financial, Methode, and Metagenomi and Encourages Investors to Contact the Firm (GlobeNewswire)
Jun-03-24 04:30PM	Is Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now? (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-29-24 04:00PM	Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 10:54PM	MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results (GlobeNewswire)
May-04-24 10:49AM	Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 06:04AM	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) -12.36%
May-01-24 04:00PM	Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems (GlobeNewswire)
01:53PM	Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight (FierceBiotech.com)
Apr-08-24 08:00AM	Metagenomi to Present at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 09:16AM	Metagenomi Reports Business Updates and Full Year 2023 Financial Results (GlobeNewswire)
Feb-29-24 04:30PM	Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-13-24 04:35PM	Metagenomi Announces Closing of Initial Public Offering (GlobeNewswire)
Feb-08-24 10:16PM	Metagenomi Announces Pricing of Initial Public Offering (GlobeNewswire)

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wein Matthew	See Remarks	Jun 06 '25	Sale	1.75	199	348	16,693	Jun 09 07:04 PM
Noonberg Sarah B.	Chief Medical Officer	Jun 06 '25	Sale	1.75	5,239	9,168	109,135	Jun 09 06:57 PM
Wapnick Pamela	Chief Financial Officer	Jun 06 '25	Sale	1.75	1,576	2,758	72,108	Jun 09 06:54 PM
Thomas Brian C.	Chief Executive Officer	Jun 06 '25	Sale	1.75	10,785	18,874	2,517,491	Jun 09 06:50 PM
Irish Jian	See Remarks	Jun 06 '25	Sale	1.75	6,390	11,182	315,543	Jun 09 06:20 PM
Wein Matthew	See Remarks	Mar 05 '25	Sale	1.87	930	1,744	9,467	Mar 07 04:38 PM
Wapnick Pamela	Chief Financial Officer	Mar 05 '25	Sale	1.87	1,808	3,390	59,684	Mar 07 04:36 PM
Wapnick Pamela	Chief Financial Officer	Dec 05 '24	Sale	1.86	1,559	2,900	61,492	Dec 06 04:24 PM
Wapnick Pamela	Chief Financial Officer	Sep 05 '24	Sale	2.88	6,265	18,043	63,051	Sep 06 05:14 PM

MGX

Metagenomi Inc

Upgrade your FINVIZ experience